Talk:Otamixaban

Lancet
- head to head with UFH & 2b3a (eptifibatide). This was mainly an efficacy/safety study, and the abstract suggests that phase III trials will probably happen now. I'm not entirely sure why one would use an intravenous anticoagulant rather than LMWH, and nor am I clear why this phase II trial went into the Lancet. But there we are, and it is probably notable enough to be discussed here. JFW | T@lk  11:06, 6 September 2009 (UTC)